|
|
沙库巴曲缬沙坦治疗心房颤动作用机制和疗效的研究进展
|
Abstract:
心房颤动(简称房颤)是临床常见的心律失常之一，显著增加了心血管事件和死亡的风险。目前维持房颤窦性心律的方法有射频消融术和抗心律失常药物治疗，但药物及手术治疗均存在较高的复发率，难以达到较满意的治疗效果。沙库巴曲缬沙坦作为一种血管紧张素受体–脑啡肽酶抑制剂(ARNI)，可同时抑制脑啡肽酶和阻断血管紧张素受体，现已有研究显示沙库巴曲缬沙坦治疗心力衰竭及高血压的同时，有助于改善房颤患者心脏结构及心脏功能，减少新发房颤及降低房颤复发率。本文综述了沙库巴曲缬沙坦对于房颤治疗的作用机制及疗效的研究进展。
Atrial fibrillation (AF) is one of the most common clinical arrhythmias that significantly increases the risk of cardiovascular events and death. At present, there are radiofrequency ablation and antiarrhythmic drug therapy to maintain the sinus rhythm of atrial fibrillation. However, both drug and surgical treatments have high recurrence rates, making it difficult to achieve satisfactory therapeutic outcomes. As an angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan can inhibit neprilysin and block angiotensin receptors at the same time. Studies have shown that sacubitril/valsartan in the treatment of heart failure and hypertension can help improve heart structure and heart function in patients with atrial fibrillation, reduce new atrial fibrillation and reduce the recurrence rate of atrial fibrillation. This article reviews the research progress on the mechanism of action and efficacy of sacubitril/valsartan in the treatment of atrial fibrillation.
| [1] | Staerk, L., Sherer, J.A., Ko, D., Benjamin, E.J. and Helm, R.H. (2017) Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation Research, 120, 1501-1517. https://doi.org/10.1161/circresaha.117.309732 |
| [2] | Wei, Y., Zhou, G., Wu, X., Lu, X., Wang, X., Wang, B., et al. (2023) Latest Incidence and Electrocardiographic Predictors of Atrial Fibrillation: A Prospective Study from China. Chinese Medical Journal, 136, 313-321. https://doi.org/10.1097/cm9.0000000000002340 |
| [3] | Guo, Y., Tian, Y., Wang, H., Si, Q., Wang, Y. and Lip, G.Y.H. (2015) Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China: New Insights into the Global Burden of Atrial Fibrillation. Chest, 147, 109-119. https://doi.org/10.1378/chest.14-0321 |
| [4] | Quintanilla, J.G., Shpun, S., Jalife, J. and Filgueiras-Rama, D. (2021) Novel Approaches to Mechanism-Based Atrial Fibrillation Ablation. Cardiovascular Research, 117, 1662-1681. https://doi.org/10.1093/cvr/cvab108 |
| [5] | Li, L., Lou, Q., Liu, G., Lv, J., Yun, F., Li, T., et al. (2020) Sacubitril/Valsartan Attenuates Atrial Electrical and Structural Remodelling in a Rabbit Model of Atrial Fibrillation. European Journal of Pharmacology, 881, Article ID: 173120. https://doi.org/10.1016/j.ejphar.2020.173120 |
| [6] | von Lueder, T.G., Wang, B.H., Kompa, A.R., Huang, L., Webb, R., Jordaan, P., et al. (2015) Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction after Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. Circulation: Heart Failure, 8, 71-78. https://doi.org/10.1161/circheartfailure.114.001785 |
| [7] | Tanai, E. and Frantz, S. (2015) Pathophysiology of Heart Failure. Comprehensive Physiology, 6, 187-214. |
| [8] | Seki, T., Goto, K., Kansui, Y., Ohtsubo, T., Matsumura, K. and Kitazono, T. (2017) Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats. Journal of the American Heart Association, 6, e006617. https://doi.org/10.1161/jaha.117.006617 |
| [9] | D’Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F.L., Perlini, S. and Senni, M. (2017) Neprilysin Inhibition in Heart Failure: Mechanisms and Substrates Beyond Modulating Natriuretic Peptides. European Journal of Heart Failure, 19, 710-717. https://doi.org/10.1002/ejhf.799 |
| [10] | Soliman, E.Z., Rahman, A.F., Zhang, Z., Rodriguez, C.J., Chang, T.I., Bates, J.T., et al. (2020) Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation. Hypertension, 75, 1491-1496. https://doi.org/10.1161/hypertensionaha.120.14766 |
| [11] | Li, X., Zhu, Q., Wang, Q., Zhang, Q., Zheng, Y., Wang, L., et al. (2020) Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice. Cardiovascular Drugs and Therapy, 34, 629-640. https://doi.org/10.1007/s10557-020-06995-x |
| [12] | Cachorro, E., Günscht, M., Schubert, M., Sadek, M.S., Siegert, J., Dutt, F., et al. (2023) CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2. Circulation Research, 132, 400-414. https://doi.org/10.1161/circresaha.122.322031 |
| [13] | Mustafa, N.H., Jalil, J., Zainalabidin, S., Saleh, M.S.M., Asmadi, A.Y. and Kamisah, Y. (2022) Molecular Mechanisms of Sacubitril/Valsartan in Cardiac Remodeling. Frontiers in Pharmacology, 13, Article 892460. https://doi.org/10.3389/fphar.2022.892460 |
| [14] | Chang, C., Wu, T., Zhou, S., Doshi, R.N., Lee, M., Ohara, T., et al. (2001) Nerve Sprouting and Sympathetic Hyperinnervation in a Canine Model of Atrial Fibrillation Produced by Prolonged Right Atrial Pacing. Circulation, 103, 22-25. https://doi.org/10.1161/01.cir.103.1.22 |
| [15] | Swissa, M., Zhou, S., Paz, O., Fishbein, M.C., Chen, L.S. and Chen, P. (2005) Canine Model of Paroxysmal Atrial Fibrillation and Paroxysmal Atrial Tachycardia. American Journal of Physiology-Heart and Circulatory Physiology, 289, H1851-H1857. https://doi.org/10.1152/ajpheart.00083.2005 |
| [16] | Wang, J., Jiang, C., Li, S., Wang, Z., Wang, Y., Lai, Y., et al. (2023) Systolic Blood Pressure Time in Target Range and Incident Atrial Fibrillation in Patients with Hypertension: Insights from the SPRINT Trial. Hypertension, 80, 2306-2314. https://doi.org/10.1161/hypertensionaha.123.21651 |
| [17] | Emdin, C.A., Callender, T., Cao, J. and Rahimi, K. (2015) Effect of Antihypertensive Agents on Risk of Atrial Fibrillation: A Meta-Analysis of Large-Scale Randomized Trials. Europace, 17, 701-710. https://doi.org/10.1093/europace/euv021 |
| [18] | De Vecchis, R., Paccone, A. and Di Maio, M. (2020) Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiology Research, 11, 213-218. https://doi.org/10.14740/cr1073 |
| [19] | Li, Q., Fang, Y., Peng, D., Li, L., Deng, C., Yang, H., et al. (2023) Sacubitril/Valsartan Reduces Susceptibility to Atrial Fibrillation by Improving Atrial Remodeling in Spontaneously Hypertensive Rats. European Journal of Pharmacology, 952, Article ID: 175754. https://doi.org/10.1016/j.ejphar.2023.175754 |
| [20] | Liu, X., Liu, H., Wang, L., Zhang, L. and Xu, Q. (2022) Role of Sacubitril-Valsartan in the Prevention of Atrial Fibrillation Occurrence in Patients with Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE, 17, e0263131. https://doi.org/10.1371/journal.pone.0263131 |
| [21] | Yang, L., Zhang, M., Hao, Z., Wang, N. and Zhang, M. (2022) Sacubitril/Valsartan Attenuates Atrial Structural Remodelling in Atrial Fibrillation Patients. ESC Heart Failure, 9, 2428-2434. https://doi.org/10.1002/ehf2.13937 |
| [22] | Sun, Q., Cui, W., Zhang, X., Tian, Y., Huang, G., He, W., et al. (2024) A Systematic Review and Meta-Analysis of Renin-Angiotensin System Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation. Journal of Cardiovascular Pharmacology, 83, 220-227. https://doi.org/10.1097/fjc.0000000000001517 |
| [23] | 黄伟鹏, 陈扬波, 周浩粤, 等. 沙库巴曲缬沙坦治疗持续性房颤的临床研究[J]. 心血管病防治知识, 2022, 12(23): 18-20. |
| [24] | Chen, Q., Chen, Y., Qin, F., Du, H., Gan, C., Zhou, B., et al. (2022) Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients with Persistent Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 9, Article 870203. https://doi.org/10.3389/fcvm.2022.870203 |
